Lung cancer
Confirm Trial | 2021 | Lung - Mesothelioma |
CHECKMATE 743 trial, ipi/nivo for mesothelioma | 2021 | Lung - Mesothelioma |
Impower 133 | 2018 | Lung - SCLC |
CASPIAN | 2021 | Lung - SCLC |
PROFILE 1014 trial, crizot vs chemo | 2014 | Lung NSCLC - ALK |
ASCEND-4 trial, cerit vs chemo | 2017 | Lung NSCLC - ALK |
Alex trial, alect vs crizo | 2017 | Lung NSCLC - ALK |
ALTA-1L , briga vs crizo | 2018 | Lung NSCLC - ALK |
Crown trial, lorla vs crizo | 2020 | Lung NSCLC - ALK |
FLAURA trial | 2018 | Lung NSCLC - EGFR |
ADAURA trial, adjuvant Osimertinib | 2020 | Lung NSCLC - EGFR |
Docetaxel in second line | 2000 | Lung NSCLC - advanced |
Pemetrexed in recurrent advanced NSCLC | 2004 | Lung NSCLC - advanced |
Scagliotti trial | 2008 | Lung NSCLC - advanced |
REVEL trial | 2014 | Lung NSCLC - advanced |
KEYNOTE-024 | 2016 | Lung NSCLC - advanced |
KEYNOTE-407 | 2018 | Lung NSCLC - advanced |
KEYNOTE-189 | 2018 | Lung NSCLC - advanced |
KEYNOTE-042 | 2019 | Lung NSCLC - advanced |
CheckMate 227 | 2019 | Lung NSCLC - advanced |
MYSTIC trial | 2020 | Lung NSCLC - advanced |
Impower110 trial | 2020 | Lung NSCLC - advanced |
CheckMate 9LA trial | 2021 | Lung NSCLC - advanced |
IMPOWER 010 trial, adj atezo | 2021 | Lung NSCLC - perioperative |
Pemetrexed in recurrent advanced NSCLC
Shepherd HN et al, JCO, 2004, PMID:15117980
Lung NSCLC - advanced
Background. Phase 3 RCT included 571 patients with recurrent advanced NSCLC with squam and non-squam histologies.
Arm A: Pemetrexed 500 mg/m2 q3wk
Arm B: Docetaxel 75 mg/m2
mPFS: 2.9 months for each arm
mOS: 8.3mo vs 7.9mo, P=not significant
ORR: 9.1% and 8.8%
Main adverse events. Grade ≥3 neutropenia (5% vs 40%, A vs B), febrile neutropenia (2% vs 13) need for GCS factor (3% vs 19%), and hair loss (6% vs 38%).
Pulled analysis. Scagliotti G et al, Oncologist, 2009, PMID:19221167
Non-squamous NSCLC mOS: 9.3mo vs 8.0mo, HR 0.78, 95%CI 0.61-1.00
Squamous NSCLC mOS: 6.2mo vs 7.4mo, HR 1.56, 95% CI 1.08-2.26
Conclusion. Pemetrexed provides similar efficacy as docetaxel in patients with recurrent advanced non-squamous NSCLC
Summarized by Veli Bakalov, MD